DEPSERT

Depression,Obsessive compulsive disorder,Panic disorder with or without agoraphobiaPosttraumatic stress disorder,Social anxiety disorder,Premenstrual dysmorphic disorder

Oral Depression Adult: Initially, 50 mg once daily, may increase in steps of 50 mg at wkly intervals. Max: 200 mg daily.  Child: For obsessive-compulsive disorder: 6-12 yr: Initially, 25 mg once daily; 13-17 yr: Initially, 50 mg once daily. May increase dose at intervals of at least 1 wk, to a max of 200 mg/day. If somnolence is noted, give at bedtime.  Hepatic impairment: Dosage reduction may be required. Oral Obsessive compulsive disorder Adult: Initially, 50 mg once daily, may increase in steps of 50 mg at wkly intervals. Max: 200 mg daily.  Child: For obsessive-compulsive disorder: 6-12 yr: Initially, 25 mg once daily; 13-17 yr: Initially, 50 mg once daily. May increase dose at intervals of at least 1 wk, to a max of 200 mg/day. If somnolence is noted, give at bedtime.  Hepatic impairment: Dosage reduction may be required. Oral Panic disorder with or without agoraphobia Adult: Initially, 25 mg daily, increased after 1 wk to 50 mg daily. May increase in steps of 50 mg at wkly intervals. Max: 200 mg daily.  Hepatic impairment: Dosage reduction may be required.  Oral Posttraumatic stress disorder Adult: Initially, 25 mg daily, increased after 1 wk to 50 mg daily. May increase in steps of 50 mg at wkly intervals. Max: 200 mg daily.  Hepatic impairment: Dosage reduction may be required.  Oral Social anxiety disorder Adult: Initially, 25 mg daily, increased after 1 wk to 50 mg daily. May increase in steps of 50 mg at wkly intervals. Max: 200 mg daily.  Hepatic impairment: Dosage reduction may be required.  Oral Premenstrual dysmorphic disorder Adult: Initially, 50 mg daily. May be given throughout the menstrual cycle or only during the luteal phase. May increase by 50 mg each cycle if needed. Max: 150 mg daily for continuous dosing or 100 mg daily for luteal phase-only dosing. Patients who require 100 mg daily for luteal phase-only dosing should always start with 50 mg daily for the 1st 3 days of each luteal phase dosing period.  Hepatic impairment: Dosage reduction may be required.

May be taken with or without food.

Symptoms include nausea, vomiting and CNS excitation. May lead to death.

Children <18 yr. Poorly controlled epilepsy.

Children <18 yr. Poorly controlled epilepsy.

Nausea, anorexia, dyspepsia, constipation, diarrhoea, dry mouth, flatulence, vomiting, ejaculation failure, increased sweating, somnolence, agitation, insomnia, headache, dizziness, fatigue, anxiety, nervousness, tremor, paraesthesia, decreased libido, rash, hot flushes, blurred vision.

May increase risk of delirium when used with antimuscarinics. Increased risk of extrapyramidal symptoms and neuroleptic malignant syndrome when used with aripiprazole. Serum levels may be reduced bycarbamazepine. Concurrent use with dihydroergotamine or linezolid may lead to serotonin syndrome. May increase serum levels of lamotrigine and risk of toxicity. May increase serum levels of olanzapine, pimozide,risperidone, methadone, clozapine and amiodarone. Plasma levels may be increased by cimetidine andritonavir. May increase the anticoagulant activity of warfarin and acenocoumarol. Potentially Fatal: Concomitant admin with MAOIs can result in serious serotonin syndrome.

Category B: Either animal-reproduction studies have not demonstrated a foetal risk but there are no controlled studies in pregnant women or animal-reproduction studies have shown an adverse effect (other than a decrease in fertility) that was not confirmed in controlled studies in women in the 1 st  trimester (and there is no evidence of a risk in later trimesters).

Oral: Store at 15-30°C.

Sertraline has a potent and selective inhibitory action on CNS neuronal reuptake of 5-HT resulting in increased 5-HT concentrations at the synaptic clefts, leading to sustained activity at the postsynaptic receptor sites and improvement of depression. Reduction of serotonin turnover (in brain) also contributes to its action. Its long half-life allows once daily admin. Absorption: Absorbed slowly from the GI tract (oral); plasma concentrations peak 4.5-8.5 hr after oral admin. Distribution: Body tissues (wide), enters breast milk. Protein-binding: 98%. Metabolism: Extensive hepatic first-pass metabolism; demethylation to N-desmethylsertraline (inactive) then to glucuronide conjugates. Excretion: Via urine and faeces (as metabolites); elimination half-life: about 26 hr.

Antidepressants

N06AB06 - sertraline; Belongs to the class of selective serotonin reuptake inhibitors. Used in the management of depression

*sertraline information: Note that there are some more drugs interacting with sertraline sertraline sertraline brands available in India Always prescribe with Generic Name : sertraline, formulation, and dose (along with brand name if required)

Co-admin with food increases peak plasma concentration of sertraline. Plasma levels are increased by grapefruit juice.